Showing resilience
The world is still impacted by the Covid-19 pandemic, our industry included. But Elekta's solid performance with positive order growth and increased profitability during the first quarter is a clear sign of our resilience and the strong underlying demand for our products. Elekta has a vital role to play for precision radiation medicine solutions - now in this time of transition and in a future situation when life will be normalized in our markets. We act forcefully to mitigate the short-term effects of the pandemic and continue to invest in innovation for long-term competitiveness.
Gustaf Salford
Acting President and CEO
First quarter
·
Covid-19 continued to have a negative effect on Elekta's business
·
Gross order intake amounted to
·
Net sales were
·
Gross margin amounted to 45.9 (42.6) percent
·
EBITA increased by 23 percent to
·
Earnings per share was
·
Cash flow after continuous investments improved by
·
At today's AGM the Board of Directors proposes a dividend of
No significant events after the quarter
[image] [1] After continuous investments
[2] Before / after dilution
[3 ]Based on constant currency
[4 ]Compared to last rolling twelve months period
# # #
For further information, please contact:
Head of Investor Relations
+46 76 611 76 25
cecilia.ketels@elekta.com
Johan Adebäck
Acting CFO
+46 70 873 33 21
johan.adeback@elekta.com
This is information that
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in
https://news.cision.com/elekta/r/interim-report--may-july-2020-21,c3181218
https://mb.cision.com/Main/35/3181218/1297288.pdf
https://news.cision.com/elekta/i/group-summary,c2817221
(c) 2020 Cision. All rights reserved., source